News & Events

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

FairJourney Biologics co-authors a Nature Medicine paper entitled: A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017 Aug 21. doi: 10.1038/nm.4390.
(https://www.ncbi.nlm.nih.gov/pubmed/28825717)

Learn more about us

FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate.

Get in touch with us
This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.